Role of radiation therapy in retroperitoneal sarcomas.
Historically, patients with retroperitoneal sarcomas have had a poor prognosis. Surgical resection continues to be the standard treatment for these tumors. However, their anatomic location and large size at presentation often make complete surgical resection infeasible. Even with complete gross removal of tumor, most patients will experience local failure. Adjuvant radiation therapy has been used to improve local control rates. In the postoperative setting, radiation doses to the tumor bed are limited by radiation tolerances of surrounding normal tissues. Extrapolation of data from soft-tissue sarcomas at other sites suggests that delivery of higher radiation doses, in combination with surgery, may favorably affect local control. Preoperative radiation therapy, in combination with brachytherapy or intraoperative radiation therapy at the time of surgical resection, allows for the safe delivery of higher doses of radiation than is possible in the postoperative setting. These approaches make it possible to maximize the likelihood of local control and cure while minimizing normal tissue toxicity.
Clark
J A
JA
Department of Radiation Oncology, University of North Carolina, School of Medicine, Chapel Hill, USA.
Tepper
J E
JE
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D001918:Brachytherapy; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D006801:Humans; D007430:Intraoperative Care; D009367:Neoplasm Staging; D010166:Palliative Care; D011182:Postoperative Care; D011300:Preoperative Care; D018714:Radiotherapy, Adjuvant; D012186:Retroperitoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery
D000970:Antineoplastic Agents